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Abstract. Recent evidence suggests that numerous long 
non-coding RNAs (lncRNAs) are dysregulated in cancer, and 
have critical roles in tumour development and progression. 
The present study investigated the ghrelin receptor antisense 
lncRNA growth hormone secretagogue receptor opposite strand 
(GHSROS) in breast cancer. Reverse transcription-quantitative 
polymerase chain reaction revealed that GHSROS expression 
was significantly upregulated in breast tumour tissues 
compared with normal breast tissue. Induced overexpression 
of GHSROS in the MDA-MB-231 breast cancer cell line 
significantly increased cell migration in vitro, without affecting 
cell proliferation, a finding similar to our previous study on lung 
cancer cell lines. Microarray analysis revealed a significant 
repression of a small cluster of major histocompatibility 
class II genes and enrichment of immune response pathways; 
this phenomenon may allow tumour cells to better evade the 
immune system. Ectopic overexpression of GHSROS in the 
MDA-MB-231 cell line significantly increased orthotopic 
xenograft growth in mice, suggesting that in vitro culture 
does not fully capture the function of this lncRNA. This study 
demonstrated that GHSROS may serve a relevant role in breast 
cancer. Further studies are warranted to explore the function 
and therapeutic potential of this lncRNA in breast cancer 
progression.
Introduction
The human genome produces coding and non-coding 
RNA (ncRNA) transcripts; however, ncRNAs represent the 
predominant RNA species (1). Long ncRNAs (lncRNAs) 
are >200 nucleotides in length, have low protein-coding 
potential, and often exhibit spatial- and temporal-specific 
expression patterns (2). They are important regulators of gene 
expression, acting through a range of different mechanisms, 
in cis or trans (3,4). Given their broad role in a diverse range 
of biological processes, it is appreciated that they serve major 
roles in physiology and disease (5). Notably, a large number 
of lncRNAs have been reported to mediate cancer-associated 
processes (3). However, the role and expression patterns of the 
majority of lncRNAs in cancer remain largely unknown.
Breast cancer is the most commonly diagnosed cancer and a 
leading cause of cancer-associated mortality in women (6). Given 
the significant incidence of breast cancer in the population, there 
is a need to explore the therapeutic potential of novel molecular 
targets, particularly for triple-negative breast cancer, which is 
diagnosed in 15% of patients with breast cancer (7). Due to a 
lack of targeted therapies, these patients require more aggressive 
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treatment regimens (7). Historically, molecular classification 
and therapeutic targeting of breast cancer-associated genes 
has focused on protein-coding genes, which represent <1% of 
the genome (8). It is now appreciated that many lncRNAs are 
feasible biomarkers and targets for molecular therapies (9-12). 
A key example includes HOX transcript antisense intergenic 
RNA (HOTAIR), which is upregulated in primary and 
metastatic breast tumours (13-15). Overexpression of HOTAIR 
in breast cancer activates an oestrogen receptor (ER)-associated 
transcriptional program, to enhance cancer growth and 
tamoxifen resistance in breast cancer (16). Similarly, the highly 
conserved and abundant lncRNA metastasis-associated lung 
adenocarcinoma transcript 1 (MALAT1) is upregulated in a 
broad range of tumour types, including metastatic breast cancer, 
and stimulates cell proliferation and migration (17). Furthermore, 
targeting MALAT1 in a mouse model of mammary carcinoma 
using modified antisense oligonucleotides (ASOs) significantly 
reduces breast cancer metastasis and slows primary tumour 
growth (18). Taken together, these studies highlight the value 
of studying the expression and function of lncRNAs in breast 
cancer.
The lncRNA growth hormone secretagogue receptor 
(GHSR) opposite strand (GHSROS) (19) is a single-exon gene 
antisense to the intronic region of GHSR; GHSR is also known as 
the ghrelin receptor gene (19). Our previous study demonstrated 
that GHSROS expression is elevated in non-small cell lung 
cancer and that its induced overexpression increases migration 
in lung adenocarcinoma cell lines (19). However, to the best 
of our knowledge, the expression pattern and functional role 
of GHSROS in breast cancer remains unknown. The present 
study analysed the expression of GHSROS in breast tissues 
and derived cell lines, and determined the effects of GHSROS 
overexpression in vitro (MDA-MB-231 and MCF10A cell lines) 
and in vivo (MDA-MB-231 tumour xenografts in mice).
Materials and methods
Cell culture. Cell lines were obtained from the American Type 
Culture Collection (ATCC). The MDA-MB-231 (HTB-26), 
MDA-MB-468 (HTB-132) and MDA-MB-453 (HTB-131) 
breast cancer cell lines were maintained in Dulbecco's 
modified Eagle's medium:Nutrient Mixture F-12 medium 
(DMEM/F12) supplemented with 10% foetal bovine serum 
(FBS), 100 U/ml penicillin G and 100 µg/ml streptomycin 
(all from Thermo Fisher Scientific, Inc., Waltham, MA, USA). 
The MCF10A breast-derived non-tumourigenic cell line 
(CRL-10317) was maintained in DMEM/F12 supplemented 
with 5% heat-inactivated horse serum, 50 U/ml penicillin G, 
100 µg/ml streptomycin, 10 µg/ml bovine insulin (all from Thermo 
Fisher Scientific, Inc.), 0.5 µg/ml hydrocortisone, 200 µg/ml 
cholera toxin (both from Sigma Aldrich; Merck KGaA) and 
20 ng/ml epidermal growth factor (Thermo Fisher Scientific, 
Inc.). The T-47D (HTB-133) and MCF-7 (HTB-22) cell lines 
were maintained in RPMI-1640 medium supplemented with 
10% FBS, 100 U/ml penicillin G, 100 µg/ml streptomycin 
and 10 µg/ml bovine insulin (Thermo Fisher Scientific, 
Inc.). The HMEC human mammary epithelial cell-derived, 
non-malignant cell line (PCS-600-010) was grown in HuMEC 
Ready Medium and Supplement kit (Thermo Fisher Scientific, 
Inc.). All cell lines were maintained at 37˚C in a humidified 
incubator (Panasonic) containing 5% CO2; cells were grown in 
tissue culture flasks (Corning, Inc.), and passaged at 2‑ to 3‑day 
intervals upon reaching 70% confluence using TrypLE Select 
(Thermo Fisher Scientific, Inc.). Cell morphology and viability 
were monitored by microscopic observation and regular 
Mycoplasma testing was performed (Universal Mycoplasma 
Detection kit; ATCC). Approval for cell line use was granted 
by the Queensland University of Technology (QUT) Human 
Research Ethics Committee (Brisbane, Australia).
Production of GHSROS‑overexpressing cell lines. For 
gain-of-function studies, full-length GHSROS was generated as 
previously described (19). The full-length GHSROS transcript, 
amplified from the A549 (CCL‑185; ATCC) lung adenocarcinoma 
cell line, was cloned into the pTargeT mammalian expression 
vector (Promega Corporation). MDA-MB-231 and MCF10A 
cell lines were transfected with 1 µg GHSROS-pTargeT plasmid 
DNA or vector alone (empty vector) using Lipofectamine 
LTX (Invitrogen; Thermo Fisher Scientific, Inc.) as per the 
manufacturer's instructions. Cells (2x105/well) were seeded in 
a 6-well plate 24 h prior to transfection. Following incubation 
at room temperature for 5 min, cells were transfected for 
24 h at 37˚C in Lipofectamine LTX and further selected with 
geneticin (G418; Invitrogen; Thermo Fisher Scientific, Inc.) at 
concentrations of 500 µg/ml for MCF10A and 600 µg/ml for 
MDA-MB-231 cells. Transfected cells were grown in the presence 
of G418 for ≥2 weeks prior to the performance of functional 
analyses. For in vivo xenograft experiments, MDA-MB-231 
cells stably overexpressing luciferase pGL4.51[luc2/CMV/Neo] 
(MDA-MB-231luc) were obtained (provided by Dr Eloïse Dray, 
QUT). pReceiver‑Lv105 lentiviral vectors (containing full-length 
GHSROS or no insert) pre-packaged in lentiviral particles 
were purchased from GeneCopoeia, Inc. Briefly, to optimise 
transduction, a titration of 0.1-10 µl viral particles was performed 
in the PC3 prostate cancer cell line (CRL-1435; ATCC) and 
the lowest, most viable dose was used. MDA-MB-231 cells 
were seeded at 50‑60% confluence and were transduced with 
GHSROS or empty vector control lentiviral constructs at a 
multiplicity of infection of 1 in the presence of 8 µg/ml polybrene 
(Sigma-Aldrich; Merck KGaA) according to the manufacturer's 
protocol. After 48 h at 37˚C, transduced cells were selected with 
1 µg/ml puromycin (Invitrogen; Thermo Fisher Scientific, Inc.) 
and expanded. GHSROS expression was confirmed ~3 weeks 
after selection by reverse transcription-quantitative polymerase 
chain reaction (RT-qPCR), then every 2-3 weeks and prior to 
every functional experiment.
RNA extraction and RT‑qPCR. Cell lines were centrifuged 
at 133 x g for 5 min and total RNA was extracted from cell 
pellets using an RNeasy Plus Mini kit and a genomic DNA 
(gDNA) eliminator spin column (Qiagen GmbH). Total RNA 
was quantified using a NanoDrop ND‑1000 spectrophotometer 
(NanoDrop Technologies; Thermo Fisher Scientific, Inc., 
Wilmington, DE, USA), diluted 1:5 in RNase-free water, and 
frozen at ‑80˚C until further use. To remove contaminating 
gDNA, 1 µg RNA was treated with DNase prior to cDNA 
synthesis with Superscript III (Invitrogen; Thermo Fisher 
Scientific, Inc.); RT was performed according to the 
manufacturer's protocol. RT-qPCR was performed with 
SYBR-Green PCR Master Mix (Qiagen GmbH) using primers 
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listed in Table I on an AB7500 FAST sequence detection 
thermal cycler (Applied Biosystems; Thermo Fisher Scientific, 
Inc., Waltham, MA, USA) or a ViiA Real-Time PCR system 
(Applied Biosystems; Thermo Fisher Scientific, Inc.). PCR 
cycles were performed under the following conditions: 10 min 
at 95˚C; 40 cycles of 15 sec at 95˚C and 1 min at 60˚C, followed 
by melting curve analysis. All experiments were performed 
in triplicate. A negative control (water instead of template) 
was used for each primer set. Baseline and quantification 
cycle (Cq) values were obtained using ABI 7500 Prism and the 
relative expression levels of mRNA were calculated using the 
comparative 2-ΔΔCq method (20). Expression was normalised 
to the housekeeping gene β-actin (ACTB). Statistical analyses 
were performed using GraphPad Prism v.6.01 software 
(GraphPad Software, Inc.).
GHSROS expression in human tissue specimens. The 
expression of GHSROS in human breast tissue was quantified 
by RT-qPCR (as aforementioned) using cDNA panels of breast 
tumour and normal breast tissue samples. Briefly, TissueScan 
Cancer Survey Tissue qPCR panels BCRT101, BCRT102, 
BCRT103 and BCRT104 were arrayed onto a single 384-well 
reaction plate by OriGene Technologies, Inc. Data are expressed 
as mean fold-change using the comparative 2-ΔΔCq method 
(compared to non-malignant control tissue on the same plate 
and normalised to ACTB).
Cell proliferation assays. Proliferation assays were performed 
using an xCELLigence real-time cell analysis (RTCA) DP 
instrument (ACEA Biosciences, Inc.). This system employs 
sensor impedance technology to quantify the status of the cell 
using a unit-less parameter termed the cell index (CI) (21). 
The CI represents the status of the cell based on the measured 
relative alterations in electrical impedance that occur in the 
presence and absence of cells in the wells [generated by the 
software, according to the formula CI = (Zi-Z0)/15 Ω, where 
Zi is the impedance at an individual point of time during 
the experiment and Z0 is the impedance at the start of the 
experiment] (21,22). Impedance is measured at three different 
frequencies (10, 25 and 50 kHz). Briefly, 5x103 cells were 
trypsinised, seeded into a 96-well plate (E-plate) and grown 
for 48 h at 37˚C in 150 µl growth media. The CI was measured 
every 15 min and all experiments were performed in triplicate, 
with at least three independent repeats.
Cell migration assays. Migration assays were performed using 
an xCELLigence RTCA DP instrument (ACEA Biosciences, 
Inc.), and cell invasion and migration plates (CIM-Plate®; 
ACEA Biosciences, Inc.). Briefly, 5x104 cells/well in 150 µl 
serum-free media were seeded on the upper electronically 
integrated Boyden chamber above a membrane with a pore 
size of 8-µm. The lower chamber contained 160 µl media 
supplemented with 10% FBS as a chemoattractant. The CI was 
measured every 15 min for 18 h (as an indication of the rate 
of cell migration onto the underside of the top chamber). All 
experiments were performed in triplicate, with at least three 
independent repeats.
Oligonucleotide microarray analysis. Oligonucleotide micro-
array analysis was performed using RNA extracted from 
MDA-MB-231 cell lines overexpressing GHSROS or vector 
controls. The MDA-MB-231 breast cancer cell line (three 
biological replicates) was transfected independently three 
times with GHSROS-pTargeT or empty pTargeT vector as 
aforementioned, and RNA was extracted and its purity anal-
ysed using an Agilent 2100 Bioanalyzer (Agilent Technologies, 
Inc.). Total RNA (500 ng) was processed and hybridised to 
Affymetrix Human Gene Arrays 1.0 by the Ramaciotti Centre 
for Gene Function Analysis (Sydney, Australia). The array 
(n=3, GHSROS-pTargeT and empty control) was quantile 
normalised and log2-transformed using the R statistical 
programming language v3.12 (www.r-project.org). Gene 
annotations were obtained from the National Center for 
Biotechnology Information (Platform GPL6244; downloaded 
September 2017; www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GPL6244). Differential expression was determined 
Table I. Primer sequences used in the present study.
Primer Gene name Primer sequence (5'-3')
GHSROS Growth hormone secretagogue F: ACATTCAGCAAATCCAGTTAATGACA
 receptor opposite strand R: CGACTGGAGCACGAGGACACTTGA
GHSROS-RT linker Growth hormone secretagogue  CGACTGGAGCACGAGGACACTGACAACAG
 receptor opposite strand  AATTCACTACTTCCCCAAA
ACTB β-actin (housekeeping gene) F: ACTCTTCCAGCCTTCCTTCCT
  R: CAGTGATCTCCTTCTGCATCCT
HLA‑DRB3 MHC class II, DR β3 QIAGEN QuantiTect Primer Assay
HLA‑DRA MHC class II, DR α QIAGEN QuantiTect Primer Assay
HLA‑DPB1 MHC, class II, DP β1 QIAGEN QuantiTect Primer Assay
HLA‑DPA1 MHC class II, DP α1 QIAGEN QuantiTect Primer Assay
TBX3 T-box 3 QIAGEN QuantiTect Primer Assay
HTR1F 5-hydroxytryptamine receptor 1F QIAGEN QuantiTect Primer Assay
TENM1 Teneurin transmembrane protein 1 QIAGEN QuantiTect Primer Assay
F, forward primer; R, reverse primer; RT, reverse transcription; MHC, major histocompatibility complex.
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using R package ‘limma’ v3.33.12 (23). Differentially expressed 
genes were defined as an absolute fold‑change ≥1.5 and P≤0.05.
To identify associations between differentially expressed 
genes, STRING (v10.5) functional analysis (24) was 
implemented. STRING integrates predicted and experimentally 
confirmed relationships between proteins that are likely to 
contribute to a common biological purpose. Using default 
parameters, differentially expressed genes were mapped into 
the STRING user interface and interactions were partitioned 
into distinct clusters using k-means analysis (25). Interaction 
networks were exported into Inkscape (v0.91; inkscape.org). 
To test for gene enrichment, differentially expressed genes 
were analysed using the Kyoto Encylopedia of Genes and 
Genomes (KEGG) (26) pathway database within the STRING 
functional analysis tool. STRING categorises KEGG pathway 
terms and calculates an ‘enrichment score’ or EASE score (a 
modified Fisher's exact test‑derived P‑value).
Orthotopic mammary fat pad in vivo xenografts in mice. 
Experiments were approved by the University of Queensland 
(Brisbane, Australia) and QUT animal ethics committees 
(TRI/QUT/328/16). Mice were housed under specific 
pathogen-free conditions in individually ventilated cages 
(Tecniplast S.p.A.) at room temperature (20‑23˚C), 40‑60% 
relative humidity and under a 12-h light/dark cycle. Food and 
water were provided ad libitum. MDA-MB-231-GHSROS or 
MDA-MB-231-Vector cell lines were injected at a 1:1 ratio with 
growth factor-reduced Matrigel (Corning, Inc.) (n=8-10/cell line) 
directly into the right inguinal mammary fat pad of 3-week old 
female NOD.Cg-Prkdc SCID IL-2rgtm1WjL/SzJ (NSG) mice 
(weight, 20-25 g; generated by the Jackson Laboratory; provided 
by Animal Resource Centre). Tumour growth was measured 
twice weekly with digital calipers (ProSciTech Pty Ltd.) and 
tumour volume was calculated using a formula for the volume 
of an ellipse: V = π/6(d1 x d2)3/2, where d1 and d2 represent 
perpendicular tumour measurements (27). In addition, tumour 
size and growth were monitored weekly by bioluminescent 
imaging (28). Briefly, mice were injected intraperitoneally 
with 150 mg/kg firefly luciferase substrate D-Luciferin 
(PerkinElmer, Inc.) diluted in PBS (Thermo Fisher Scientific, 
Inc.) 10 min prior to imaging. Following anaesthesia with 
isoflurane, bioluminescent imaging was performed using 
an IVIS Spectrum in vivo imaging system (PerkinElmer, 
Inc.) (28). Images were analysed using the associated Living 
Image Software (PerkinElmer, Inc.; version 4.7.1). Briefly, total 
flux in photons/sec (p/s) was used as a surrogate for primary 
tumour size and determined within a defined region of interest, 
individually, for each mouse (28). Animals were sacrificed 
once tumour volume reached 1,000 mm3, or earlier according 
to other ethical endpoints.
Statistical analyses. Data are presented as the mean ± standard 
error of the mean of at least two independent experiments, and were 
evaluated by Student's t-test, one-way or two-way ANOVA with 
Dunnett's or Bonferroni's post hoc test, Mann-Whitney-Wilcoxon 
test or Kruskal-Wallis test with Dunn's post hoc test for multiple 
groups. P≤0.05 was considered to indicate a statistically significant 
difference. Statistical analyses were performed using GraphPad 
Prism v.6.01 (GraphPad Software, Inc.).
Results
GHSROS expression is elevated in breast cancer tissue and 
breast cancer‑derived cell lines. To investigate the role of 
GHSROS in breast cancer, RT-qPCR was performed on 
cDNA array panels of normal breast and breast cancer tissues. 
GHSROS expression could be detected in three out of 16 normal 
breast tissue samples (Fig. 1A). In contrast, 47% (83/176) of 
tumours expressed GHSROS at significantly higher levels than 
the normal breast tissues examined (P=0.030). In addition, 
GHSROS was significantly elevated in stage I (P=0.0077) 
breast cancer samples (Fig. 1B; Table II). GHSROS expression 
Figure 1. GHSROS is expressed at low levels in normal breast tissue and at higher levels in breast cancer (BCa). (A) GHSROS expression in clinical BCa 
(n=176) and N breast samples (n=16), as determined by RT-qPCR. *P≤0.05, Mann‑Whitney‑Wilcoxon test. (B) GHSROS expression stratified by clinical stage 
of BCa, as determined by RT-qPCR. N (n=16), stage I (n=35), stage II (n=74), stage III (n=57) and stage IV (n=10). *P≤0.05, Kruskal‑Wallis with Dunn's post hoc 
test. (C) GHSROS expression in the MCF10A and HMLE normal-breast derived cell lines, and the MDA-MB-231, MCF-7, T-47D, BT474 and MDA-MB-453 
BCa cell lines compared to the MCF-10A cell line, as determined by RT-qPCR. ***P≤0.001 vs. MCF‑10A, one‑way ANOVA with Dunnett's post hoc test. All 
experiments were performed independently three times (n=3) with three replicates per experiment (n=3). Data are presented as the mean ± standard error of 
the mean, and relative expression levels were determined using the comparative 2-ΔΔCq method. Samples were normalised using β-actin. BCa, breast cancer; 
GHSROS, growth hormone secretagogue receptor opposite strand; N, normal; RT-qPCR, reverse transcription-quantitative polymerase chain reaction.
INTERNATIONAL JOURNAL OF ONCOLOGY  55:  1223-1236,  2019 1227
was not associated with a range of other clinical parameters 
and features, including age, hormone receptor status [ER, 
progesterone receptor (PR) and human epidermal growth factor 
receptor 2 (HER2)] and metastasis (Table II). Similar to the 
normal tissue specimens, very low levels of GHSROS expression 
were observed in the MCF10A and HMEC non-malignant cell 
Figure 2. GHSROS promotes cell migration, but not cell proliferation, in MCF10A and MDA-MB-231 breast cancer cell lines in vitro. (A) Relative expres-
sion of GHSROS in MDA-MD-231-GHSROS, MDA-MB-231-Vector, MCF10A-GHSROS and MCF10A-Vector cell lines. Expression was normalised to 
the housekeeping gene β-actin using the comparative 2-ΔΔCq method of quantification. Results are relative to each vector control. (B) Proliferation was not 
significantly increased in the MCF10A or MDA‑MB‑231 cell lines overexpressing GHSROS compared to cells expressing vector alone when assessed using 
an xCELLigence real-time cell analyser for 72 h. (C) GHSROS overexpression increased MCF10A migration across a porous membrane (pore size, 8 µM). 
Left panel, representative plot of raw cell index impedance measurements from 0 to 20 h after cell seeding. Right panel, GHSROS overexpression increased 
cell migration at 18 h. (D) GHSROS overexpression increased MDA-MB-231 migration across a porous membrane. Left panel, representative plot of raw cell 
index impedance measurements from 0 to 20 h after overexpression of GHSROS. Right panel, GHSROS overexpression increased cell migration 18 h after 
passaging. Data are presented as the mean ± standard error of the mean (n=3). *P≤0.05, **P≤0.01 vs. vector control; Student's t‑test. GHSROS, growth hormone 
secretagogue receptor opposite strand.
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lines compared with most breast cancer cell lines (Fig. 1C). 
GHSROS was expressed at higher levels in triple-negative 
(ER-, PR- and HER2-) MDA-MB-231 (2.71±0.27 fold-change, 
P=0.3601) and MDA-MB-453 (33.60±3.33 fold-change, 
P=0.0001) cell lines, and in the ER-/PR+/HER2+ BT474 
(8.36±0.94 fold-change, P=0.0001) and ER+/PR+/HER2+ 
MCF7 (3.28±0.65 fold-change, P=0.0652) cell lines compared 
with the MCF10A cell line (Fig. 1C).
Ectopic overexpression of GHSROS in breast‑derived 
cell lines promotes in vitro migration, but not in vitro 
proliferation. In order to investigate GHSROS function, 
MCF10A normal breast-derived cells and MDA-MB-231 
breast cancer cells stably overexpressing full-length GHSROS 
(MCF10A-GHSROS and MDA-MB-231-GHSROS), and 
corresponding vector control cell lines (MCF10A-Vector 
and MDA-MB-231-Vector), were generated (Fig. 2A). The 
MDA-MB-231 cell line was chosen for overexpression studies 
as it has relatively low endogenous levels of GHSROS. Using 
real-time cell analysis (xCELLigence system), it was observed 
that GHSROS overexpression did not significantly increase 
the in vitro proliferation rate of cultured MCF10A (0.96±0.04 
fold-change, P=0.18) and MDA-MD-231 cell lines (0.89±0.81 
fold-change, P=0.29) over 72 h (Fig. 2B). Conversely, 
overexpression of GHSROS significantly increased the rate 
of migration of MCF10A (1.71±0.43 fold-change, P=0.040; 
Fig. 2C) and MDA-MB-231 (1.34±0.26 fold-change, P=0.045; 
Fig. 2D) cell lines over an 18-h period.
GHSROS regulates genes associated with cancer and the 
immune response. To gain further insight into the function of 
GHSROS in breast cancer, gene expression microarrays were 
performed on RNA isolated from GHSROS-overexpressing 
MDA-MB-231 cells and vector control cells. A total of 76 genes 
were differentially regulated by >1.5-fold in MDA-MB-231 
cells overexpressing GHSROS (36 upregulated and 
40 downregulated) (Fig. 3A and Table III).
The most upregulated genes in the microarray were 5-hydroxy-
tryptamine (5-HT) receptor 1F (HTR1F, 3.1 fold-change, 
P=0.0040) and EPH receptor A3 (EPHA3, 2.3 fold-change, 
P=0.0190) (Table III). Significant upregulation of HTR1F was 
verified by RT-qPCR in the MDA-MB-231-GHSROS cell 
line (19.2±1.173 fold-change, P=0.0002; Fig. 3B). Conversely, 
HTR1F expression was reduced in MCF10A-GHSROS cells 
(-2.68±0.002 fold-change, P>0.999; Fig. 3B), although this 
finding was not statistically significant. Notably, a number 
of established oncogenes were differentially expressed in the 
MDA-MB-231-GHSROS microarray data. These included 
teneurin transmembrane protein 1 (TENM1), which was 
downregulated in MDA-MB-231-GHSROS cells (-2.00 
fold-change, P=0.0238. These data were validated by RT-qPCR 
in MDA-MB-231-GHSROS cells (-2.65±0.286 fold-change, 
P=0.0048), and TENM1 was similarly downregulated in 
MCF10A-GHSROS cells (-2.31±0.262 fold-change, P=0.020; 
Fig. 3B). The T-box transcription factor gene T-box 3 (TBX3) 
is associated with breast cancer cell migration and growth (29) 
and was upregulated (1.5 fold-change, P=0.0041; Table III) 
in the MDA-MB-231-GHSROS microarray. Upregulation of 
TBX3 was confirmed by RT‑qPCR in MDA‑MB‑231‑GHSROS 
cells (5.60±0.82 fold-change, P=0.025; Fig. 3B); however, 
TBX3 expression was not altered in MCF10A-GHSROS 
cells (Fig. 3B).
Table II. GHSROS expression, as determined by reverse transcription-quantitative polymerase chain reaction, and clinicopatho-
logical parameters in breast cancer and normal breast clinical specimens.
Clinicopathological Total number Sample n demonstrating Sample % demonstrating
parameters (n) expression expression P-value
N/T 16/176 3/83 12.5/47.2 0.0300a
Clinical stage
  N 16   2 12.5 NA
  I 35 20 57.1 0.0406a
  II 74 33 44.6 0.2364
  III 57 27 47.4 0.1359
  IV 10   1 10 >0.9999
Clinical features
  ER+/ER- 74/59 32/33 43.2/55.9 0.3829
  PR+/PR- 67/57 27/29 40.3/50.9 0.3402
  HER2+/HER2- 42/93 18/44 42.9/47.3 0.6185
  ER-, PR-, HER2-/Other 33/152 17/66 51.5/43.4 0.7110
  M/Non-M 17/159 5/76 29.4/47.8 0.4236
GHSROS expression in tumour tissues stratified by clinical stage and clinical features was compared to normal breast tissues. All tumour 
tissue was compared against normal breast tissue. Clinical features were assessed within tumour tissues. P-values were calculated using the 
Kruskal-Wallis with Dunn's post hoc test for multiple comparisons. ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; 
M, metastatic tumour; non‑M, non‑metastasised tumour (primary breast tumour confined to site); N, normal breast tissue; NA, non‑applicable; 
PR, progesterone receptor; T, tumour tissue. aP≤0.05 compared with N. For some samples, clinical information was missing; therefore, these 
samples were excluded from that analysis. The mean age at diagnosis was 55.8 years. 
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In the present dataset, it was observed that a single 
probe matched to several class II major histocompatibility 
complex (MHC) genes. A number of MHC class II genes 
were significantly repressed by GHSROS [including MHC, 
class II, DR β3 (HLA‑DRB3), -2.7 fold-change, P=0.0068; 
MHC, class II, DR β1, -2.7 fold-change, P=0.0063; MHC, 
class II, DR α (HLA‑DRA), -2.4 fold-change, P=0.0058; MHC, 
class II, DP β1 (HLA‑DPB1), -2.3 fold-change, P=0.039; 
Table III]. MHC gene loci are complex; their exons are highly 
similar and person-to-person variation in exon sequences can 
confound microarray probe hybridisation (30,31). To firmly 
establish which MHC-II genes were differentially expressed 
upon forced GHSROS overexpression, selected genes were 
validated by RT‑qPCR. Using RT‑qPCR, it was confirmed 
that GHSROS overexpression in MDA-MB-231 cells induced 
downregulation of the MHC-II genes HLA‑DRA (-4.62±0.024 
fold-change, P<0.0001), HLA‑DPB1 (-4.53±0.30 fold-change, 
P<0.0001), MHC, class II, DP α1 HLA‑DPA1 (-3.69±0.02 
fold-change, P<0.0001) and HLA‑DRB3 (-3.84±0.02 
fold-change, P<0.0001) (Fig. 3B). These transcripts were not 
detected in the MCF10A-GHSROS or MCF10A-Vector cell 
lines, which is consistent with the fact that normal breast 
epithelial tissue is typically MHC-II negative (32).
Differentially expressed genes identified by microarray 
analysis were interrogated for biological interactions using 
the STRING tool (24). Within the functional protein-protein 
interaction (PPI) network a small, distinct interaction 
was detected between the MHC-II gene set (HLA‑DRA, 
HLA‑DPA1 and HLA‑DPB1) and protein tyrosine phosphatase, 
non-receptor type 22 (lymphoid) (Fig. 3C; expected 
interactions, 7; observed interactions, 15; PPI enrichment 
P=0.0099, hypergeometric test). KEGG pathway analysis of 
56 genes analysed in STRING demonstrated that the 40 genes 
downregulated in MDA-MB-231-GHSROS cells were enriched 
for pathways typically associated with the expression of MHC-II 
genes (Fig. 3C; Table IV), including ‘antigen processing 
and presentation’ [Benjamini-Hochberg corrected P-value, 
Benjamini-Hochberg false discovery rate (BH-FDR)=0.0020], 
Figure 3. GHSROS significantly differentially regulates 76 genes in the MDA‑MB‑231 breast cancer cell line. (A) Scatter plot visualization of induced (red) or 
repressed (green) genes identified by microarray. The threshold was set at as log2 1.5 fold‑change and Q≤0.05 (Benjamini Hochberg‑adjusted P‑value). EPHA3, 
HTR1F, FKBP10, LOC645188, ZNF585B and HLA genes were affected by GHSROS. (B) Expression levels of TBX3, HTR1F, TENM1, HLA‑DRA, HLA‑DRB3, 
HLA‑DPA1 and HLA‑DPB1 were measured in cultured MDA-MB-231-GHSROS, MDA-MB-231-Vector, MCF10A-Vector and MCF10A-GHSROS cells by 
reverse transcription-quantitative polymerase chain reaction. Expression was normalised to the housekeeping gene β-actin. Results are relative to the respec-
tive vector control. Data are presented as the mean ± standard error of the mean (n=2); ***P≤0.001 vs. vector control, two‑way ANOVA with Bonferroni's post 
hoc analysis. (C) STRING network consisting of 56 proteins encoded by genes differentially expressed in MDA-MB-231-GHSROS cells. Nodes represent dif-
ferentially expressed genes. Genes induced (red border) or repressed (blue border) by GHSROS are indicated. Lines between protein nodes indicate biological 
associations inferred or experimentally demonstrated. Differentially expressed HLA genes are represented by blue nodes in the centre of the cluster. ΕPHA3, 
EPH receptor A3; FKBP10, FK506 binding protein 10; GHSROS, growth hormone secretagogue receptor opposite strand; HLA‑DRA, MHC, class II, DR α; 
HLA‑DRB3, MHC, class II, DR β3; HLA‑DPA1, MHC, class II, DP α1; HLA‑DPB1, MHC, class II, DP β1; HTR1F, 5-hydroxytryptamine receptor 1F; MHC, 
major histocompatibility complex; TBX3, T-box 3; TENM1, teneurin transmembrane protein 1; ZNF585B, zinc finger protein 585B.
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Table III. Differentially expressed genes in MDA-MB-231-GHSROS cells compared with in empty vector control cells.
    Affymetrix
Gene symbol Gene name Fold-change P-value probe
HTR1F 5-Hydroxytryptamine receptor 1F 3.12 0.0040 8081067
EPHA3 EPH receptor A3 2.27 0.0190 8081081
FKBP10 FK506 binding protein 10 2.23 0.0032 8007154
SHISA3 Shisa family member 3 2.13 0.0046 8094870
MYO1D Myosin ID 2.07 0.0111 8014115
STK26 Serine/threonine protein kinase 26 1.91 0.0008 8169949
BICC1 BicC family RNA binding protein 1 1.81 0.0021 7927681
PTGS2 Prostaglandin-endoperoxide synthase 2 1.79 0.0106 7922976
EPCAM Epithelial cell adhesion molecule 1.77 0.0089 8098439
SH3BGRL2 SH3 domain binding glutamate rich protein like 2 1.70 0.0008 8120833
FZD3 Frizzled class receptor 3 1.68 0.0021 8145611
PRKAA2 Protein kinase AMP-activated catalytic subunit α2 1.63 0.0118 7901720
SLC16A6 Solute carrier family 16 member 6 1.63 0.0045 8017843
SLC4A4 Solute carrier family 4 member 4 1.63 0.0056 8095585
GPR63 G protein-coupled receptor 63 1.62 0.0092 8128316
MIPOL1 Mirror-image polydactyly 1 1.62 0.0013 7973985
LGR5 Leucine rich repeat containing G protein-coupled receptor 5 1.58 0.0184 7957140
PLCB1 Phospholipase C β1 1.58 0.0222 8060854
ADAM23 ADAM metallopeptidase domain 23 1.56 0.0083 8047788
SLITRK4 SLIT and NTRK like family member 4 1.52 0.0070 8175574
GNAL G protein subunit α L 1.52 0.0006 8020164
AMOT Angiomotin 1.52 0.0128 8174576
MGAT4A mannosyl (α-1,3-)-glycoprotein β- 1.52 0.0418 8054135
 1,4-N-acetylglucosaminyltransferase, isozyme A
ULK2 Unc-51 like autophagy activating kinase 2 1.50 0.0008 8013399
OR2A9P/// Olfactory receptor family 2 subfamily A member 9 pseudogene/// 1.50 0.0373 8136983
OR2A20P olfactory receptor family 2 subfamily A member 20 pseudogene
ZNF704	 Zinc	finger	protein	704	 1.50	 0.0032	 8151496
TBX3 T-box 3 1.49 0.0041 7966690
SUPT20HL1/// SPT20 homolog, SAGA complex component-like 1///SPT20 1.48 0.0245 8166509
SUPT20HL2 homolog, SAGA complex component-like 2
SUPT20HL1/// SPT20 homolog, SAGA complex component-like 1///SPT20 1.48 0.0245 8171844
SUPT20HL2 homolog, SAGA complex component-like 2
TENM2 Teneurin transmembrane protein 2 1.47 0.0391 8109752
PDK3 Pyruvate dehydrogenase kinase 3 1.47 0.0220 8166511
OR2A9P///OR2A20P Olfactory receptor family 2 subfamily A member 9 pseudogene/// 1.47 0.0334 8143629
 olfactory receptor family 2 subfamily A member 20 pseudogene
TPD52L1 Tumour protein D52-like 1 1.46 0.0024 8121838
TMEM56-RWDD3/// TMEM56-RWDD3 readthrough///transmembrane 1.46 0.0363 7903162
TMEM56 protein 56
CLEC2B C-type lectin domain family 2 member B 1.45 0.0498 7961083
CSF3 Colony stimulating factor 3 1.45 0.0052 8006999
PICK1 Protein interacting with PRKCA 1 -1.47 0.0386 8072989
MAOA Monoamine oxidase A -1.48 0.0217 8166925
CRISPLD1 Cysteine rich secretory protein LCCL domain containing 1 -1.49 0.0009 8146967
MSLN Mesothelin -1.50 0.0059 7992071
ZNF558 Zinc finger protein 558 ‑1.53 0.0070 8033667
PTPN22 Protein tyrosine phosphatase, non-receptor type 22 -1.54 0.0004 7918657
NDP NDP, norrin cystine knot growth factor -1.54 0.0004 8172220
IFI27 Interferon α inducible protein 27 -1.56 0.0225 7976443
ZNF814 Zinc finger protein 814 ‑1.56 0.0033 8039692
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Table III. Continued.
    Affymetrix
Gene symbol Gene name Fold-change P-value probe
PARP15 poly(ADP-ribose) polymerase family member 15 -1.56 0.0147 8082086
CPT1C Carnitine palmitoyltransferase 1C -1.56 0.0267 8030448
RNU5D‑1 RNA, U5D small nuclear 1 -1.57 0.0412 7915592
ARHGAP6 Rho GTPase activating protein 6 -1.58 0.0042 8171313
MEST Mesoderm specific transcript ‑1.63 0.0026 8136248
STOM stomatin -1.67 0.0110 8163896
NLRP2 NLR family pyrin domain containing 2 -1.72 0.0001 8031398
MUSK Muscle associated receptor tyrosine kinase -1.79 0.0389 8157173
CSF2RA Colony stimulating factor 2 receptor α subunit -1.80 0.0030 8165735
CSF2RA Colony stimulating factor 2 receptor α subunit -1.80 0.0030 8176306
LYPD6B LY6/PLAUR domain containing 6B -1.97 0.0188 8045664
TENM1 Teneurin transmembrane protein 1 -1.97 0.0238 8174937
TGIF2LY/// TGFB induced factor homeobox 2 like, Y-linked///TGFB -1.97 0.0002 8176397
TGIF2LX induced factor homeobox 2 like, X-linked
HLA‑DPB1 Major histocompatibility complex, class II, DP β1 -1.99 0.0485 8118594
TGIF2LY/// TGFB induced factor homeobox 2 like, Y-linked///TGFB -1.99 0.0002 8168646
TGIF2LX induced factor homeobox 2 like, X-linked
ADGRF1 Adhesion G protein-coupled receptor F1 -2.00 0.0038 8126820
SLC38A4 Solute carrier family 38 member 4 -2.04 0.0081 7962559
HLA‑DPB1 Major histocompatibility complex, class II, DP β1 -2.07 0.0403 8178220
SPANXC///SPANXD SPANX family member C///SPANX family member D -2.10 0.0027 8175558
HLA‑DPA1 Major histocompatibility complex, class II, DP α1 -2.22 0.0466 8125556
HLA‑DPA1 Major histocompatibility complex, class II, DP α1 -2.22 0.0466 8178891
HLA‑DPA1 Major histocompatibility complex, class II, DP α1 -2.22 0.0470 8180100
HLA‑DPB1 Major histocompatibility complex, class II, DP β1 -2.31 0.0391 8179519
ZNF585B zinc finger protein 585B ‑2.31 0.0001 8036389
HLA‑DRA/// Major histocompatibility complex, class II, DR α///major -2.35 0.0065 8118548
HLA‑DQA1 histocompatibility complex, class II, DQ α1
HLA‑DRA/// Major histocompatibility complex, class II, DR α///major -2.36 0.0058 8179481
HLA‑DQA1 histocompatibility complex, class II, DQ α1
LOC645188 Uncharacterised LOC645188 -2.39 0.0003 8170257
HLA‑DRA/// Major histocompatibility complex, class II, DR α///major -2.55 0.0072 8178193
HLA‑DQA1 histocompatibility complex, class II, DQ α1
LOC105369230/// HLA class II histocompatibility antigen, DRB1-7β chain///major -2.62 0.0054 8180003
HLA‑DRB6/// histocompatibility complex, class II, DR β6 (pseudogene)///major
HLA‑DRB5/// histocompatibility complex, class II, DR β5///major
HLA‑DRB4/// histocompatibility complex, class II, DR β4///major
HLA‑DRB3/// histocompatibility complex, class II, DR β4///major
HLA‑DRB1/// histocompatibility complex, class II, DR β3///major
LOC105369230/// histocompatibility complex, class II, DR β1///HLA class II
HLA‑DRB5/// histocompatibility antigen, DRB1-7β chain///major
HLA‑DRB4/// histocompatibility complex, class II, DR β5///major
HLA‑DRB3/// histocompatibility complex, class II, DR β4///major
HLA‑DRB1/// histocompatibility complex, class II, DR β3///major
HLA‑DQB1 histocompatibility complex, class II, DR β1///major
 histocompatibility complex, class II, DQ β1
LOC105369230/// HLA class II histocompatibility antigen, DRB1-7 β chain///major -2.66 0.0063 8178811
HLA‑DRB6/// histocompatibility complex, class II, DR β6 (pseudogene)///major
HLA‑DRB5/// histocompatibility complex, class II, DR β5///major
HLA‑DRB4/// histocompatibility complex, class II, DR β4///major
HLA‑DRB3/// histocompatibility complex, class II, DR β3///major
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‘asthma’ (BH-FDR=0.0011) and ‘graft-versus-host disease’ 
(BH-FDR=0.0011) pathways (Table IV).
GHSROS increases orthotopic breast xenograft growth. 
In order to investigate the effect of GHSROS on tumour 
growth in vivo an orthotopic xenograft model was used (33). 
MDA-MB-231luc-GHSROS and MDA-MB-231luc-Vector 
cells were injected into the mammary fat pad of NSG 
mice (Fig. 4A). Compared to vector controls, mammary fat 
pad xenograft tumour volumes [measured by total flux (p/s)] 
were significantly increased in MDA‑MB‑231luc‑GHSROS 
mice at day 28 post-implantation (Mann-Whitney, P=0.0002), 
day 42 post‑implantation (P≤0.0001) and at the experimental 
(ethical) endpoint (day 49, P≤0.0001) (Fig. 4B). No gross 
metastases were observed in either experimental group. Upon 
excision, the MDA-MB-231luc-GHSROS tumours weighed 
significantly more post mortem (Mann-Whitney-Wilcoxon 
test, P=0.017; Fig. 4C).
Figure 4. GHSROS promotes orthotopic MDA-MB-231 xenograft tumour growth in vivo. (A) NOD.Cg-Prkdc SCID IL-2rgtm1WjL/SzJ mice were injected in 
the mammary fat pad with MDA-MB-231luc cell lines stably overexpressing GHSROS (n=10) or empty vector (n=10). Representative IVIS images showing 
total flux (bioluminescence) at day 49 (endpoint) demonstrating that tumours were larger in mice with GHSROS-overexpressing tumours. (B) Time course for 
MDA-MB-231luc-GHSROS (n=10) and luc-Vector control (n=10) mammary fat pad xenograft tumour bioluminescence. Tumour bioluminescent imaging [total 
flux (p/s)] was measured using the IVIS Spectrum in vivo imaging system. ***P≤0.001 vs. vector control, two‑way ANOVA with Bonferroni's post hoc analysis. 
(C) Tumour weights of MDA-MB-231 xenografts (GHSROS overexpressing, n=10; vector, n=10) at the end point. *P<0.05 vs. vector control, Mann-Whitney-Wilcoxon 
test. Data are presented as the mean ± standard error of the mean. GHSROS, growth hormone secretagogue receptor opposite strand; p/s, photons/sec.
Table III. Continued.
    Affymetrix
Gene symbol Gene name Fold-change P-value probe
HLA‑DRB1/// histocompatibility complex, class II, DR β1///HLA class II
LOC105369230/// histocompatibility antigen, DRB1-7β chain///major
HLA‑DRB5/// histocompatibility complex, class II, DR β5///major
HLA‑DRB4/// histocompatibility complex, class II, DR β4///major
HLA‑DRB3/// histocompatibility complex, class II, DR β3///major
HLA‑DRB1/// histocompatibility complex, class II, DR β1///major
HLA‑DQB1 histocompatibility complex, class II, DQ β1
LOC105369230/// HLA class II histocompatibility antigen, DRB1-7β chain///major -2.71 0.0068 8178802
HLA‑DRB6/// histocompatibility complex, class II, DR β6 (pseudogene)///major
HLA‑DRB5/// histocompatibility complex, class II, DR β5///major
HLA‑DRB4/// histocompatibility complex, class II, DR β4///major
HLA‑DRB3/// histocompatibility complex, class II, DR β3///major
HLA‑DRB1/// histocompatibility complex, class II, DR β1///HLA class II
LOC105369230/// histocompatibility antigen, DRB1-7β chain///major histocompatibility
HLA‑DRB5/// complex, class II, DR β5///major histocompatibility complex,
HLA‑DRB4/// class II, DR β4///major histocompatibility complex, class II,
HLA‑DRB3/// DR β3///major histocompatibility complex, class II, DR β1///major
HLA‑DRB1/// histocompatibility complex, class II, DQ β1
HLA‑DQB1
Bold text represents higher expression in MDA-MB-231-GHSROS cells; unbold text represents lower expression in MDA-MB-231-GHSROS 
cells. P-values were obtained using the R package ‘limma’ (moderated t-test).
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Discussion
Our previous study demonstrated that GHSROS, a lncRNA 
derived from a gene antisense to the ghrelin receptor gene, is 
expressed by non-small cell lung tumours and increases lung 
cancer cell migration in vitro (19). Similarly, in this study it 
was demonstrated that GHSROS was expressed in breast 
cancer and promoted in vitro cell line migration. GHSROS 
also promoted MDA-MB-231 breast cancer cell xenograft 
tumour growth and altered the expression of cancer-associated 
and immune genes. While lncRNAs are rarely highly 
conserved, nor abundantly expressed, they can serve integral 
regulatory roles in a large array of cellular processes, including 
pathological conditions such as tumourigenesis (34,35). In a 
previous study, genome‑wide RNA‑seq profiling of 22 paired 
tumour and non-malignant tissues from ER+ breast cancer 
samples demonstrated that the expression of natural antisense 
transcript lncRNAs are increased in tumour samples (36), 
suggesting that they may have important regulatory roles.
A number of lncRNAs differentially expressed in 
breast cancer function as critical mediators of breast cancer 
tumourigenesis (35,37,38). For example, the lncRNAs H19 (39), 
MALAT1 (40), HOTAIR (41) and taurine upregulated 1 (42) 
have a higher gene expression in breast cancer tissues and 
derived cell lines (41,43). lncRNAs have also been proposed as 
potential breast cancer biomarkers. MALAT1 is an abundant 
and highly conserved lncRNA that can be detected in the 
serum of patients with breast cancer and at much higher levels 
than in patients with benign breast disease (40). Although 
the present study did not detect a direct relationship between 
GHSROS expression and clinical parameters (including ER, 
PR and HER2 status), further studies interrogating a larger 
patient cohort are warranted.
GHSROS increased in vitro cell migration, but not 
proliferation, of the MDA-MB-231 breast cancer cell line and 
the non-tumourigenic, normal-breast derived MCF10A cell line. 
Our previous study observed similar effects in non-small-cell 
lung carcinoma cell lines overexpressing GHSROS (19). 
MDA-MB-231 breast cancer cells metastasise from the 
mammary fat pads of NSG mice, with gross tumours observed 
in multiple tissues, including the lungs, lymph nodes and liver, 
53 days after implantation (44). This model is, therefore, useful 
for investigating the effect of gene expression on metastasis. 
In the current study, mice bearing GHSROS-overexpressing 
xenografts were euthanised 49 days after injection as they had 
reached the ethical endpoint. However, gross metastases were 
not observed and therefore, it was not possible to determine if 
GHSROS affected metastasis in these animals.
Although no changes in proliferation were observed in 
the present two-dimensional cell models, tumour size was 
significantly greater in orthotopic MDA‑MB‑231‑GHSROS 
xenograft tumours. In vitro models of cell proliferation do 
not replicate numerous aspects of cancer progression (33), 
including the tumour microenvironment and growth factors, 
which are not present in an in vitro system (45).
Microarray analysis of MDA-MB-231-GHSROS 
cells cultured in vitro was conducted to reveal potential 
GHSROS-regulated genes. The most highly upregulated gene, 
HTR1F, belongs to a subgroup of 5-HT/serotonin receptors and 
is significantly associated with breast cancer recurrence (46). 
This gene was downregulated in GHSROS-overexpressing 
MCF10A cells, which also exhibited increased in vitro 
migration, suggesting that HTR1F is unlikely to play a major 
role in GHSROS-mediated cell migration. Upregulation of 
the 5-HT signalling pathways in metastatic breast cancer is 
pro-oncogenic, stimulating pro-proliferative, invasive and 
anti-apoptotic pathways (46). Conversely, normal physiological 
levels of the ligand, 5-HT, induce growth inhibition and 
apoptosis in breast cancer cell lines, presumably by increased 
expression of its receptors (47). TBX3 is a transcription factor 
that is considered a key driver of breast cancer progression, 
which was elevated in GHSROS-overexpressing breast cancer 
cells. TBX3 is elevated in metastatic breast cancer, is correlated 
with reduced metastasis-free survival, and potently promotes 
cell survival and tumour growth in early-stage breast cancer cell 
models (29,48,49). Additionally, TBX3 overexpression stimulates 
cell migration in normal breast and breast cancer cells (49). 
Therefore, it was hypothesised that TBX3 may represent a key 
mediator of the effects of GHSROS in breast cancer.
Transcripts encoding a number of subunits of MHC-II were 
repressed in MDA-MB-231 cells overexpressing GHSROS. 
MHC-II genes encode cell surface proteins primarily involved 
in antigen presentation and adaptive immunity (30,50,51). 
Reduced tumour expression of the MHC-II complex increases 
breast tumour aggressiveness and results in poor overall 
survival (50,52). Conversely, increased MHC-II expression is 
associated with a positive prognosis in triple-negative breast 
cancer (50). Given that in vivo xenograft models using human 
cell lines require immunocompromised or syngeneic mice, 
the role of GHSROS in antitumour immunity is currently 
challenging to investigate and could not be assessed in the 
present xenograft model. Humanised mice that support human 
cell lines and patient-derived xenografts (53,54) will be critical 
in assessing if GHSROS overexpression indeed facilitates 
immune system evasion. The present study hypothesised 
that GHSROS, by downregulating critical components of the 
acquired immune system, may promote breast tumour cell 
survival.
There are several limitations to the present study. Firstly, 
gene expression was not examined between tumours and 
corresponding adjacent, normal tissue. Future studies will aim 
to detect the expression of GHSROS in larger, well-characterised 
clinical cohorts. Secondly, overexpression of GHSROS should be 
complemented by knockdown experiments, using, for example, 
short hairpin RNA or modified ASOs. We recently generated 
ASOs targeting GHSROS, revealing that these compounds 
reciprocally regulate GHSROS-mediated expression and 
function of prostate cancer cell lines (Thomas et al, unpublished 
data). We aim to assess these ASOs in a future breast cancer 
study. Finally, 3D invasion assays, complementing the 2D 
in vitro assays employed in this study, may provide critical 
further insights into the function of GHSROS. 2D assays, 
particularly invasion assays (22), are not fully representative of 
gene function and may lead to discordant results, as observed 
when comparing 2D in vitro proliferation assay data and in vivo 
xenograft tumour growth in this study. 3D invasion assays will 
be employed in a future study to further determine the function 
of GHSROS.
In conclusion, the present study examined the expression 
and function of the lncRNA GHSROS in breast cancer, 
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suggesting a potential role for GHSROS in breast cancer cell 
migration and tumour growth. These data expand on recent 
findings regarding GHSROS in lung cancer (19) and provide 
a rationale for further investigations into this lncRNA in 
cancer.
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Table IV. Enriched KEGG pathway terms for 40 genes downregulated in MDA-MB-231-GHSROS cells.
KEGG ID Pathway description Gene count BH-FDR Genes
5310 Asthma 3 0.00107a HLA‑DPA1, HLA‑DPB1, HLA‑DRA
5330 Allograft rejection 3 0.00107a HLA‑DPA1, HLA‑DPB1, HLA‑DRA
5332 Graft-versus-host disease 3 0.00107a HLA‑DPA1, HLA‑DPB1, HLA‑DRA
4940 Type I diabetes mellitus 3 0.00111a HLA‑DPA1, HLA‑DPB1, HLA‑DRA
4672 Intestinal immune network for IgA production 3 0.00119a HLA‑DPA1, HLA‑DPB1, HLA‑DRA
5150 Staphylococcus aureus infection 3 0.00132a HLA‑DPA1, HLA‑DPB1, HLA‑DRA
5320 Autoimmune thyroid disease 3 0.00132a HLA‑DPA1, HLA‑DPB1, HLA‑DRA
5416 Viral myocarditis 3 0.00146a HLA‑DPA1, HLA‑DPB1, HLA‑DRA
5321 Inflammatory bowel disease (IBD) 3 0.00185a HLA‑DPA1, HLA‑DPB1, HLA‑DRA
4612 Antigen processing and presentation 3 0.00201a HLA‑DPA1, HLA‑DPB1, HLA‑DRA
5140 Leishmaniasis 3 0.00209a HLA‑DPA1, HLA‑DPB1, HLA‑DRA
5323 Rheumatoid arthritis 3 0.00356a HLA‑DPA1, HLA‑DPB1, HLA‑DRA
5322 Systemic lupus erythematosus 3 0.00443a HLA‑DPA1, HLA‑DPB1, HLA‑DRA
5145 Toxoplasmosis 3 0.0069a HLA‑DPA1, HLA‑DPB1, HLA‑DRA
4514 Cell adhesion molecules  3 0.0114a HLA‑DPA1, HLA‑DPB1, HLA‑DRA
4145 Phagosome 3 0.0121a HLA‑DPA1, HLA‑DPB1, HLA‑DRA
5164 Influenza A 3 0.0179a HLA‑DPA1, HLA‑DPB1, HLA‑DRA
5152 Tuberculosis 3 0.0181a HLA‑DPA1, HLA‑DPB1, HLA‑DRA
5168 Herpes simplex infection 3 0.0183a HLA‑DPA1, HLA‑DPB1, HLA‑DRA
5169 Epstein-Barr virus infection 3 0.0221a HLA‑DPA1, HLA‑DPB1, HLA‑DRA
5166 HTLV-I infection 3 0.0465a HLA‑DPA1, HLA‑DPB1, HLA‑DRA
aKEGG pathway passed the 5% BH-FDR-corrected P-value. BH-FDR, Benjamini-Hochberg false discovery rate; HLA‑DPA1, MHC class II, 
DP α1; HLA‑DPB1, MHC class II, DP β1; HLA‑DRA, MHC class II, DR α; KEGG, Kyoto Encyclopedia of Genes and Genomes; MHC, major 
histocompatibility complex.
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